← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lentigen Corporation
Gaithersburg, MD
$10,357,255
Total funding
13
Grants
Funding over time
peak $4.3M · FY2006–12$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$10,357,255 · 13
By mechanism
R44$5,082,389 · 1
R42$2,652,661 · 1
R43$1,560,776 · 8
R41$1,061,429 · 3
Investigators at Lentigen Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Clinical Vector for TCR Immunotherapy Targeted to Melanoma$2,160,774
R44 · FY2011 · CA
Lentiviral-MGMT gene transfer into hematopoietic stem cells$2,150,576
R42 · FY2011 · CA
Clinical Vector for TCR Immunotherapy Targeted to Melanoma$1,729,819
R44 · FY2012 · CA
Clinical Vector for TCR Immunotherapy Targeted to Melanoma$1,191,796
R44 · FY2010 · CA
Lentiviral-MGMT gene transfer into hematopoietic stem cells$502,085
R42 · FY2010 · CA
Lentiviral gene therapy for mucopolysaccharidosis$364,844
R41 · FY2010 · DK
Lentiviral Vectors for TCR Immunotherapy Targeted to HCV$289,677
R43 · FY2007 · AI
Lentiviral Redirected T Cells for B Cancer Immunotherapy$283,753
R41 · FY2007 · CA
A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus$282,918
R43 · FY2009 · AI
Suicide of HIV-Infected Cells by TAT-Inducible shRNA$264,329
R41 · FY2006 · AI
Lentiviral Vectors for TCR Immunotherapy Targeted to melanoma$243,003
R43 · FY2006 · CA
Lentiviral engineered T cell immunotherapy in tumors overexpressing mesothelin$236,588
R43 · FY2006 · CA
Lentiviral Redirected T Cells for B Cancer Immunotherapy$148,503
R41 · FY2008 · CA
Universal MUC1 Targeted Immunotherapy$140,720
R43 · FY2009 · CA
T cell receptor gene vectors for EBV disease$134,081
R43 · FY2007 · CA
Lentiviral expressed growth factors as a novel therapy in wound healing$119,144
R43 · FY2008 · AR
Immunotherapy of CLL with lentiviral expressed CD40-ligand$114,645
R43 · FY2006 · CA